
Hims House
@himshouse • 46,818 subscribers
The home for Hims & Hers investors - $HIMS Not affiliated with $HIMS YouTube - https://t.co/lMG4U00rBY Discord - https://t.co/xjUBaTZxp3
Videos

🚨 BPC-157 and five other peptides just got the green light "It's going to be a knife fight" - Jeff Tang We discuss $HIMS, Ro, Superpower, and Enhanced; TikTok's ban of peptide content; LegitScript + Meta ads; and why anyone experimenting with peptides should carry an EpiPen. FULL INTERVIEW Jeff is a Y Combinator founder who sold his longevity meal prep company to Bryan Johnson (Bryan Johnson). Today he hosts Peptide Parties in SF + LA. Jeff was at a telehealth conference when HHS dropped the news last week, and his first reaction was "let the games begin." 01:03 - 6 peptides cleared: "It's going to be a knife fight" 02:30 - Why Hims should be Apple: best, not first 03:47 - Why the ban on BPC-157 + TB-500 blends (Wolverine Stack) will be ignored 05:56 - Peptide parties 11:24 - The 4 peptides Hims left out 14:47 - Will Ro sit out peptides?! 👀 17:15 - Hims' rivals + telehealths that hit 9-figures 20:28 - LegitScript + Meta ads 28:42 - TikTok's ban on peptide searches 34:10 - Superpower pricing vs. the gray market 39:43 - Jeff's peptide stack: tirz, tesamorelin, and cerebrolysin (made from pig brains) 45:30 - Predictions: a MOTS-c hospitalization + state-by-state rules 49:57 - What will be the top peptide in 5 years? Not financial, legal, or medical advice
Hims House77,369 Aufrufe • vor 16 Tagen

🚨 Why $HIMS may be the most asymmetric opportunity in the entire stock market Here's the full breakdown with Travis Hoium FULL INTERVIEW Travis is the founder of Asymmetric Investing, and $HIMS is his first or second biggest position, depending on the day. Travis started buying Hims in the teens in spring 2024 and has never sold a share. He calls Hims "the modern pharma company," and pitches a new idea: Hims for Kids, starting with the EpiPens that still cost his family up to $600 after insurance. Then we go through my list of worries -- slumping margins, Ro catching up, slow progress on tech & AI -- and close on peptides and what Hims could be worth in five years. 02:11 - First bought in the teens in 2024, never sold a share 08:12 - Hims = "the modern pharma company" 13:26 - Travis pitches "Hims for Kids" 22:21 - Gross margin fell from 82% to 64%. Why he's not worried 26:06 - Shipping delays & surprise charges 30:45 - Ro has caught up to Hims in credit card data 33:17 - Hims slow AI / tech progress? 36:38 - Hims should sync with every device 40:49 - Why no drug company will pay for peptide research 44:22 - Could peptides add $1 billion in revenue next year? 52:07 - Why Hims refuses to take insurance, and Ro does 53:45 - Insider buying and selling 57:03 - Why Hims could go from 2x to 10x sales Not financial, legal, or medical advice
Hims House52,951 Aufrufe • vor 20 Tagen

$HIMS CLOSED AT $28.75 LAST FRIDAY MEANWHILE, ITS STOCK TOKEN HIT $132 THIS WEEKEND ON ROBINHOOD CHAIN 😳 ... because of a memecoin called $BONER FULL INTERVIEW 🚨 WARNING: This is not a typical Hims House podcast! I wanted to do this interview because what happened on Robinhood Chain this weekend directly affected $HIMS -- and I think Hims investors should at minimum understand what happened. I sat down wit eric, an Ethereum OG and the world's largest $BONER holder, and Yoni Ben-Shimon, co-founder of LONG() My main question was the one I think most Hims investors will have: if you like Hims, why buy $BONER instead of $HIMS or the $HIMS stock token? We also get into the mechanism that triggered the spike this weekend, whether this sort of thing could happen again, and why Eric believes every major stock will eventually have a memecoin community. 01:27 - Why should Hims investors care? 03:35 - 12K Boner holders in five days 06:00 - Why buy Boner instead of the stock token 14:31 - 99% of meme coins go to zero 19:00 - Open pairing: Boner Hims 22:27 - $132 on chain vs $28.75 on the NYSE 26:44 - Could this trigger a short squeeze? 34:06 - Has anyone at Hims called? 36:25 - Every major stock gets a meme coin community Not financial, legal, or medical advice
Hims House159,331 Aufrufe • vor 2 Monaten

$HIMS 🚨 THE FDA PEPTIDES VOTE IS DAYS AWAY Peptides insider Jesse Morse, M.D. expects approval We discuss the FDA briefing document recommending *against* the 7 peptides, what the odds of approval are for each of the peptides under review (including BPC-157) and why U.S.-made API could be a major advantage for $HIMS 01:37 - FDA briefing document 03:24 - Getting peptides back in front of the FDA 08:58 - Prescribing peptides back in 2017 12:42 - Peptides safety data 16:08 - BPC-157 deep-dive and odds for approval 22:56 - TB-500 deep-dive 26:15 - Approval odds for the other 5 peptides 31:02 - Peptide efficacy data 34:40 - FDA politics and final decisions 40:30 - Peptides market size 42:48 - Training the doctors 47:20 - Shipping hurdles and gray-market risk 53:25 - Why peptides could reshape healthcare Not financial, legal, or medical advice
Hims House186,135 Aufrufe • vor 4 Monaten

$HIMS 🚨 EXCLUSIVE: On August 24, the FDA sent an official warning letter to one of America's largest gray-market peptide sellers I sat down with RetaZaktide David, founder & CEO of Peptide Partners, for his first interview about the warning letter We cover why payment processors consider peptides "riskier than gambling", how the Chinese peptide supply chain actually works, and why retatrutide is his #1 seller. Zak also responds to Martin Shkreli's claim that peptides are setting Western medicine back 70 years 🔥 FULL INTERVIEW + TIMESTAMPS 01:49 - How Zak found peptides 04:19 - 80% of vials now "fill-finished" in the US 06:15 - Just under 100K customers all-time 08:48 - Retatrutide is #1 12:33 - Zak's take on the FDA letter 20:25 - Peptides "riskier than gambling" to payment processors 25:01 - Why they now test >10 vials per batch 31:06 - All China today, India lab coming in December 31:04 - Peptide Partners' supply chain today 34:58 - American-made peptide potential pricing 40:48 - Grindr's $250 million deal 46:32 - TSA agent recognized his peptide vials 49:48 - Zak's advice to Hims & Andrew Dudum 52:22 - Why Shkreli is wrong about peptides Not financial, legal, or medical advice
Hims House47,859 Aufrufe • vor 29 Tagen

$HIMS THE PEPTIDE SUPPLY CHAIN --- JUST 5 COMPANIES IN CHINA CONTROL ~90% OF THE AMINO ACIDS 🤯 Mansi: "Before any peptide is produced, you need its API, which stands for 'active pharmaceutical ingredient', and right now China supplies most of the world's API" "The top 5 companies in China control around 90% of the protected amino acids, which is essentially the raw building block of a peptide." "You can't attach raw amino acids to each other. That's a very volatile and chaotic process... The error rate tends to compound every time you attach one amino acid to the other. So for example, BPC-157 sits at around 15 amino acids, and it tends to come out correct around 75% of the time. And Semaglutide (Ozempic) sits at 31 amino acids, and that comes out correct around 50% of the time." "This is why China wins: because they have this at massive scale to compensate for these efficiency issues." "CordenPharma in Colorado is the largest in the US. They have around 10,000 liter of SPPS reactor capacity." "But in China there's a company called WuXi AppTec, which has 100,000 liters of capacity... more than 10x larger than *the largest* synthesis plant here in the United States."
Hims House222,322 Aufrufe • vor 6 Monaten

🚨 EXCLUSIVE: $HIMS board member David Wells on why he bought $1.2M of Hims Previously, David was CFO of Netflix for 15 years 01:07 - Meet David Wells 02:30 - Why he bought $1.2M in shares 05:58 - Building a mission-driven company 09:03 - Why he accepted the offer to join the board 10:45 - Financial metrics David is tracking 12:53 - Novo deal + GLP-1s 15:13 - Peptides: best, not first 19:45 - M&A and execution risk 20:40 - What CEO Andrew Dudum does well 22:30 - Remote impact on company culture 24:22 - AI, tech, and wearables 29:55 - Lessons from Netflix 36:17 - Insider sales 10b5-1 explained 45:37 - Short interest and the bear case 48:23 - Hims in 2030 Not financial, legal, or medical advice
Hims House145,846 Aufrufe • vor 4 Monaten

🚨 THE PEPTIDE GOLD RUSH @mansizzzzle - The #1 peptide substacker & founder of Chief Longevity Officer We discuss peptide culture, the supply-chain race, and how $HIMS fits in. One of the most fun + fascinating episodes I've ever done. Thank you Mansi!! 02:09 - Background on Mansi 03:45 - Inside peptide culture 06:30 - NAD+ shots and different form factors 08:20 - Peptide culture across cities 10:54 - Dubai’s longevity gold rush 12:21 - Why peptides feel a little like crypto 16:41 - Mansi’s peptide experiments 19:50 - FDA timeline for peptide reclassification 24:46 - Why supply chain wins 26:11 - The synthesis bottleneck 28:15 - China’s scale advantage 30:29 - Why Hims bought CS Bio 31:39 - State laws 33:57 - Who wins the peptide rush 36:51 - Pricing power, tariffs, and trust 41:53 - Why gray markets persist 45:01 - Peptides with real LTV 47:51 - The Flatiron Health for peptides Not financial, legal, or medical advice
Hims House196,571 Aufrufe • vor 6 Monaten

$HIMS $LLY $NVO 🚨 OpenLoop CEO: the peptide gray market is 2-3x bigger than analyst estimates, likely $6-8 billion FULL INTERVIEW Jon Lensing is co-founder & CEO of OpenLoop, the white-label company behind 400+ telehealth brands. OpenLoop will serve more than 8 million patients this year, and is reportedly valued at >$1 billion. Jon thinks GLP-1s will become a default medication the way statins did for cholesterol, and he expects 80% of people over 30 could be on them by 2035. On peptides, Jon thinks some could be legal to compound before year-end 👀 -- but not all at once. And he sizes the gray market at $6-8 billion. 01:37 - The Shopify of virtual healthcare 04:32 - OpenLoop serving 8M patients this year 05:33 - MEDVi 07:08 - OpenLoop's January data breach 08:13 - Consumerism in healthcare 10:38 - 80% of people over 30 will be on GLP-1s 16:22 - Peptides likely this year, but not all at once 18:46 - Ready to launch peptides the day FDA allows 21:17 - Peptide API from FDA green-listed vendors 22:51 - Peptide gray market is $6 to $8 billion 27:01 - AI data moats Not financial, legal, or medical advice
Hims House67,566 Aufrufe • vor 2 Monaten

🚨 BREAKING: $HIMS CEO ANDREW DUDUM SAYS THEY ARE WORKING ON BLUETOOTH-ENABLED MEDICINE BOTTLES THAT WILL KNOW IF PEOPLE TOOK THEIR PILLS "WE'RE 12 MONTHS AWAY FROM THIS" "ALL OF IT WILL BE DOCUMENTED AND FED BACK INTO A GLOBAL $HIMS ECOSYSTEM" "WE ARE FIGURING OUT HOW TO GET THOSE BOTTLES CONNECTED" "WE ARE PARTNERING WITH ALL OF THE DEVICE PLATFORMS" "AND EVENTUALLY THESE DEVICES -- THE OURA, THE WHOOP, THE SCALES -- CAN BE MANUFACTURED FOR $10 OVERSEAS" "IT WILL BE BUILT INTO A CORE HIMS & HERS MEMBERSHIP, AND ALL OF THAT DATA COMES BACK INTO A GLOBAL ECOSYSTEM WHERE YOU HAVE AN AI CARETAKER OVERSEEING THE WHOLE THING"
Hims House92,499 Aufrufe • vor 3 Monaten

$ENHA $HIMS FULL INTERVIEW: Maximilian Martin (Maximilian Martin), CEO of Enhanced Group We discuss the inaugural Enhanced Games, the FDA peptide meeting (Max was in the room all week), why he thinks market size estimates could turn out to be low, Enhanced's international launch, and life as a public company CEO. Thanks for coming back on the show, Max! 01:38 - The Enhanced Games: an honest scorecard 06:35 - Why $ENHA stock fell 40% 10:13 - The athlete-led flywheel 11:52 - Why he flew to Washington for peptides 18:07 - Six of seven peptides recommended 20:21 - How long will FDA rulemaking take? 22:51 - Where the peptide moat actually is 30:16 - Is big pharma slowing down peptide approval? 32:14 - Being first vs being best 40:33 - Could peptides be a $10B market in 2027? 46:00 - Enhanced now live in 33 new markets 50:25 - Life as a public company CEO Not financial, legal, or medical advice
Hims House80,114 Aufrufe • vor 3 Monaten

🚨 HEDGE FUNDER IGNACIO CANTO ON THE CASE FOR $HIMS We get into the power of retail cults, Hims as Costco + Netflix, why disrupting a broken system often takes a controversial company, and why he thinks the stock is dramatically undervalued. Thank you to Ignacio for joining the pod! 01:38 - Why he never considered selling 03:41 - Buying the collapse into the teens 06:29 - Why Hims first caught his eye 10:37 - Healthcare is broken and overpriced 12:50 - Why Ignacio has added to his position 21:41 - Why price targets aren't right for Hims 27:42 - Retail cults 38:40 - Hims as Costco + Netflix 41:33 - Why Hims should own the wearable 44:25 - Regulation as a bear case 46:09 - Competition: Ro, Amazon, and others 55:30 - Why Hims could command a 10x P/S ratio Not financial, legal, or medical advice
Hims House98,395 Aufrufe • vor 4 Monaten

🚨 NEEDHAM ANALYST RYAN MACDONALD: PEPTIDES COULD BE A $30+ BILLION MARKET AND $HIMS IS POSITIONED TO WIN A BIG SHARE This is most thorough deep-dive we've done on the business side of peptides: We discuss the latest peptide news, how the FDA / PCAC process actually works, the size of the peptide opportunity, $HIMS' potential share, the Novo partnership, branded vs compounded economics, short interest, competition, valuation, and more. 🔥 01:58 - FDA briefing document breakdown 04:15 - The timeline of peptide approval 09:50 - Category 1 vs 503A Bulks List 11:34 - When will telehealths start to sell peptides? 14:25 - Sizing the peptide market 19:31 - Hims’ peptide share 21:55 - Peptide pricing & margins 24:45 - Peptides likely a 2027 revenue story 29:58 - Hims-Novo deal check-in 32:11 - Branded vs compounded GLP-1s margins 35:27 - Pills vs injectables 40:43 - International 42:04 - Hims' moat 46:22 - 2030 targets and valuation models 50:32 - Shorts, insiders, and catalysts Not financial, medical, or legal advice
Hims House85,085 Aufrufe • vor 4 Monaten

🚨 THE PEPTIDES BULL CASE FOR $HIMS Jonah Lupton - Founder & CIO of FirstWave Capital We discuss how peptides fit into Jonah's thesis for Hims, Jonah's $30K/year peptide regimen, the possibility of Hims x Lilly, retatrutide, and why he thinks Hims could 10x over the next 10 years 02:34 - How Jonah got into peptides 03:39 - Current Hims position 05:04 - Original Hims thesis in the teens 09:12 - FDA peptide timeline & July meeting 15:03 - Peptides are "80% of the thesis" 18:37 - Jonah's personal peptide stack 26:00 - Spending $30K a year on peptides 28:47 - Black market and WhatsApp China 30:25 - Gray market and the COA problem 31:05 - Why Hims wins on legitimacy 32:36 - Best, not first 32:54 - Frustration with Hims transparency 35:28 - Speed vs the Apple approach 37:45 - Surviving the Novo scare 42:46 - Branded vs compounded future 44:41 - Why Lilly matters more than Novo 50:18 - Valuation and the 2035 model 57:04 - Wrap up and other peptide plays Not financial, legal, or medical advice
Hims House124,070 Aufrufe • vor 7 Monaten

🚨 $HIMS CEO ANDREW DUDUM ON WHY HE WANTED TO IPO AND GROW THE COMPANY IN THE PUBLIC MARKETS "You have to have a stomach of steel, but more importantly, the team has to get really good very quickly at both setting quarterly targets and meeting long-term vision." "You have to be able to tell The Street with confidence, 'We're gonna hit these numbers a year out,' and then you have to hit them, or else you lose all trust." "When you step back and look at some of the biggest companies in the world... Google and Microsoft, Meta, Amazon, these companies were public within a few years of being founded." "The founders put themselves in the public markets and then had to be forced with both having a long-term vision and building a great business." "And not saying you can't do this in the private markets, but the public markets make it required. And so as a competitive person, I've loved that environment. I've loved what it's done to our team. And I think it has prepared us to be able to go after a much bigger opportunity."
Hims House79,950 Aufrufe • vor 4 Monaten

🚨 BREAKING: MARK CUBAN ON PEPTIDES: "I'M NOT A BELIEVER IN THAT SH*T" TBPN $HIMS $LLY $NVO
Hims House78,831 Aufrufe • vor 8 Monaten

🚨 WHAT IS $HIMS MOAT IF ANYONE CAN LAUNCH A TELEHEALTH STARTUP OVERNIGHT? Today I'm joined by Eli Dorf, founder of Bask Health, the software platform that powers telehealth brands from launch to payments to pharmacy fulfillment. We discuss $HIMS' real competitive advantages, the rise of the first 2-person billion-dollar telehealth brand (MEDVi), whether Hims should build a wearable, the future of GLP-1s and peptides, and whether Ro will go public. Awesome conversation -- huge thanks to Eli for joining the show. 02:18 - What Bask Health does 03:19 - Launching a telehealth brand overnight 07:21 - Can anyone copy Hims? 14:28 - Bask's business model 16:28 - Fragmentation hits telehealth margins 19:48 - Medvi's cautionary tale 21:56 - What are Hims' real moats 25:29 - Data, AI, and wearables 26:39 - Should Hims sell hardware? 30:15 - FDA pressure on GLP-1s 33:44 - Peptides as the next GLP-1 moment 36:48 - Payment processing and LegitScript 41:05 - Why peptide trust matters 43:52 - The health super-app race 47:44 - Ro vs Hims 50:45 - Will Ro go public? Not financial, legal, or medical advice
Hims House59,240 Aufrufe • vor 6 Monaten

🚨 NEW EPISODE!!! NOVO NORDISK SUES $HIMS -- PATENT ATTORNEY GASTON KROUB (Gaston Kroub) BREAKS IT DOWN 02:25 - Details of the lawsuit 07:41 - Why no preliminary injunction? 12:31 - Why did Novo file now vs. 8-9 months ago? 24:04 - Why did Novo file in Delaware? 29:21 - Likely timelines, chances of settlement or dismissal 33:20 - Worst-case scenarios 36:48 - Indemnification and supplier liability? 45:01 - FDA & DOJ pressure on compounded GLP-1s 49:46 - How Hims miscalculated the oral launch 55:00 - What to watch next
Hims House77,196 Aufrufe • vor 9 Monaten